DEK-NUP214 is considered an unfavorable prognostic marker, and patients harboring this mutation should be treated per high-risk AML protocols (two induction cycles and one intensification cycle followed by allo-HSCT) (Footnote 3, Table 7). Here, NUP214 is linked to acute myeloid leukemia.